The KMT2A gene has over 80 known fusion partners, one of which, AFDN (AF6, 6q27), activates the oncogenic RAS pathway, further promoting AML progression (Winters and Bernt, 2017). The gene discussed is KMT2A; the disease is acute myeloid leukemia.